BioNTech raises $270m in new round of funding

This article was originally published here

BioNTech, a company focused on developing personalized immunotherapies for cancer, has completed a $270m Series A round of financing.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply